Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults With Underlying Medical Conditions in the United States

Hagit Kopel, Van Hung Nguyen, Alina Bogdanov, Isabelle Winer, Catherine Boileau, Thierry Ducruet, Ni Zeng, Jessamine Winer-Jones, Daina B. Esposito, Mary Bausch-Jurken, Ekkehard Beck, Mac Bonafede, James A. Mansi
doi: https://doi.org/10.1101/2024.08.06.24311559

Article Information

doi 
https://doi.org/10.1101/2024.08.06.24311559
History 
  • August 7, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Hagit Kopel1,*,
  2. Van Hung Nguyen2,
  3. Alina Bogdanov3,
  4. Isabelle Winer3,
  5. Catherine Boileau2,
  6. Thierry Ducruet2,
  7. Ni Zeng3,
  8. Jessamine Winer-Jones3,
  9. Daina B. Esposito1,
  10. Mary Bausch-Jurken1,
  11. Ekkehard Beck1,
  12. Mac Bonafede3 and
  13. James A. Mansi1
  1. 1Moderna, Inc., Cambridge, MA, USA
  2. 2VHN Consulting Inc., Montreal, Quebec, Canada
  3. 3Veradigm, Chicago, IL, USA
  1. ↵* Corresponding author; email: james.mansi{at}modernatx.com
Back to top
Posted August 07, 2024.
Download PDF
Data/Code
Email
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults With Underlying Medical Conditions in the United States
Hagit Kopel, Van Hung Nguyen, Alina Bogdanov, Isabelle Winer, Catherine Boileau, Thierry Ducruet, Ni Zeng, Jessamine Winer-Jones, Daina B. Esposito, Mary Bausch-Jurken, Ekkehard Beck, Mac Bonafede, James A. Mansi
medRxiv 2024.08.06.24311559; doi: https://doi.org/10.1101/2024.08.06.24311559
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area